Literature DB >> 32582902

TLR2 agonists and their structure-activity relationships.

Benjamin L Lu1, Geoffrey M Williams1, Margaret A Brimble1.   

Abstract

Agonists of Toll-like Receptor 2 (TLR2) are attractive synthetic targets due to their use as adjuvants in immunotherapies to treat various diseases notably, cancer. An indepth understanding of TLR2 agonist structure-activity relationships is therefore advantageous for the methodical design of vaccines targetting the TLR2 machinery. This review aims to collate and discuss the literature regarding synthetic studies towards TLR2 agonists and the structure-activity relationships thereof. It is hoped that interested readers will gain a holistic understanding of this topic, and will prompt further efforts towards finding effective agonists of TLR2.

Entities:  

Year:  2020        PMID: 32582902     DOI: 10.1039/d0ob00942c

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  9 in total

1.  Next-Generation Diprovocims with Potent Human and Murine TLR1/TLR2 Agonist Activity That Activate the Innate and Adaptive Immune Response.

Authors:  Ming-Hsiu Yang; Jamie L Russell; Yuto Mifune; Ying Wang; Hexin Shi; Eva Marie Y Moresco; Daniel J Siegwart; Bruce Beutler; Dale L Boger
Journal:  J Med Chem       Date:  2022-06-29       Impact factor: 8.039

2.  Synthesis, structure-activity relationship studies and evaluation of a TLR 3/8/9 agonist and its analogues.

Authors:  Anindya Sarkar; Anushka C Galasiti Kankanamalage; Qian Zhang; Heng Cheng; Prasanna Sivaprakasam; Joseph Naglich; Chunshan Xie; Sanjeev Gangwar; Dale L Boger
Journal:  Med Chem Res       Date:  2021-05-18       Impact factor: 2.351

3.  Stereoisomeric Pam2CS based TLR2 agonists: synthesis, structural modelling and activity as vaccine adjuvants.

Authors:  Arshpreet Kaur; Sakshi Piplani; Deepender Kaushik; Johnson Fung; Isaac G Sakala; Yoshikazu Honda-Okubo; Surinder K Mehta; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2022-04-20

Review 4.  Peptides for Vaccine Development.

Authors:  Ian W Hamley
Journal:  ACS Appl Bio Mater       Date:  2022-02-23

Review 5.  Application and prospect of targeting innate immune sensors in the treatment of autoimmune diseases.

Authors:  Jun Liu; Hui Zhang; Yanhong Su; Baojun Zhang
Journal:  Cell Biosci       Date:  2022-05-26       Impact factor: 9.584

6.  Mimicking Native Display of CD0873 on Liposomes Augments Its Potency as an Oral Vaccine against Clostridioides difficile.

Authors:  Cansu Karyal; Panayiota Palazi; Jaime Hughes; Rhys C Griffiths; Ruby R Persaud; Patrick J Tighe; Nicholas J Mitchell; Ruth Griffin
Journal:  Vaccines (Basel)       Date:  2021-12-08

7.  Toll-like receptor 2 (TLR2) is a candidate prognostic factor in testicular germ cell tumors as well as an indicator of immune function in the tumor microenvironment.

Authors:  Hao Wu; Ze Zhang; Xin-Ying Xiao; Zi-Yi Zhang; Sheng-Lin Gao; Chao Lu; Li Zuo; Li-Feng Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 6.832

8.  Novel Synthetic Lipopeptides as Potential Mucosal Adjuvants Enhanced SARS-CoV-2 rRBD-Induced Immune Response.

Authors:  Ling Mao; Chang Liu; Jing-Yi Liu; Zi-Li Jin; Zhe Jin; Ruo-Yi Xue; Rang Feng; Guo-Cheng Li; Yan Deng; Hao Cheng; Quan-Ming Zou; Hai-Bo Li
Journal:  Front Immunol       Date:  2022-03-09       Impact factor: 7.561

9.  Akkermansia muciniphila phospholipid induces homeostatic immune responses.

Authors:  Munhyung Bae; Chelsi D Cassilly; Xiaoxi Liu; Sung-Moo Park; Betsabeh Khoramian Tusi; Xiangjun Chen; Jaeyoung Kwon; Pavel Filipčík; Andrew S Bolze; Zehua Liu; Hera Vlamakis; Daniel B Graham; Sara J Buhrlage; Ramnik J Xavier; Jon Clardy
Journal:  Nature       Date:  2022-07-27       Impact factor: 69.504

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.